Valuation: Virbac

Market Cap 2.91B 3.25B 2.69B 2.44B 4.56B 309B 4.61B 32.2B 12.82B 162B 12.18B 11.93B 514B P/E 2026 *
16.8x
P/E 2027 * 15.2x
Enterprise Value 3.02B 3.37B 2.79B 2.53B 4.73B 321B 4.78B 33.39B 13.3B 168B 12.63B 12.37B 533B EV / Sales 2026 *
1.94x
EV / Sales 2027 * 1.79x
Free-Float
49.03%
Yield 2026 *
0.5%
Yield 2027 * 0.59%
1 day-0.29%
1 week+0.72%
Current month+11.56%
1 month+14.50%
3 months+3.12%
6 months-6.84%
Current year-2.80%
1 week 344
Extreme 344
351.5
1 month 301.5
Extreme 301.5
351.5
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
448.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Date Insider Type Main position Quantity % Market Cap. Importance
4/22/24 Sell

Chief Executive Officer

810 0.0096%
4/22/24 Sell

Chief Executive Officer

140 0.0017%
4/22/24 Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%+0.72%-4.01%+28.70% 3.25B
+0.50%+1.38%+57.09%+127.73% 1,143B
+0.86%+5.14%+45.00%+84.34% 647B
-0.14%+0.42%+25.69%+101.56% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-5.97%+61.93%+37.25% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+3.08%+54.69%+71.67% 242B
+0.08%+3.67%+35.05%+104.71% 197B
Average +0.41%+0.86%+35.16%+70.41% 403.08B
Weighted average by Cap. +0.70%+0.71%+43.64%+87.31%

Financials

2026 *2027 *
Net sales 1.56B 1.73B 1.44B 1.3B 2.43B 165B 2.46B 17.21B 6.85B 86.46B 6.51B 6.37B 274B 1.65B 1.84B 1.53B 1.38B 2.58B 175B 2.61B 18.24B 7.26B 91.65B 6.9B 6.76B 291B
Net income 173M 193M 160M 145M 271M 18.38B 274M 1.91B 762M 9.62B 724M 709M 30.54B 193M 215M 178M 161M 302M 20.47B 305M 2.13B 849M 10.71B 807M 790M 34.01B
Net Debt 108M 121M 100M 90.59M 169M 11.49B 171M 1.2B 476M 6.01B 453M 443M 19.08B 39.59M 44.12M 36.6M 33.15M 61.93M 4.2B 62.68M 438M 174M 2.2B 166M 162M 6.98B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
26-10-28 €347.50 -0.29% 3,441
26-10-27 €348.50 -0.14% 2,242
26-10-26 €349.00 0.00% 2,978
26-10-23 €349.00 -0.29% 5,484
26-10-22 €350.00 +1.30% 4,566
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
347.50EUR
Average target price
410.75EUR
Spread / Average Target
+18.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock